Stability testing ensures that patients receive medication that remains effective throughout its intended use period
More than 90% of participants on 7.2 mg lost at least 5% of their body weight, and about one in three lost 25% or more
Brown-Borg HM, Rakoczy S, Wonderlich JA, Armstrong V, Rojanathammanee L
While semaglutide may reduce LDL-C by 5-10%, moderate-intensity statins typically achieve reductions of 30-50%, and high-intensity statins can lower LDL-C by 50%
doi: 10.1007/s12020-019-02175-6 110 PatouliasDStavropoulosKImprialosKKatsimardouAKalogirouM-SKoutsampasopoulosKet al
Our findings indicate that SFN ameliorates psoriasis symptoms and inflammation through the KEAP1-NRF2 pathway, suggesting a potential therapeutic role for SFN in the treatment of psoriasis